- Stocks
- Pharma & Healthcare
- Valencia Nutrit
Valencia Nutrit share price
NSE: VALENCIAPharma & HealthcareBiotechnology
Valencia Nutrit at a glance
With a market capitalisation of ₹132 Cr, it ranks 2508th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Biotechnology.
Its return on equity was 2.9% in FY25. Promoters held 64.18% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹132 CrRank 2508 on NSE
- Price to book
- 2.09×FY25
- ROE
- 2.9%FY25
- ROCE
- 3.2%FY25
- Debt to equity
- 0.04FY25
- Net profit margin
- 12.7%FY25
- Book value / share
- ₹21.54FY25
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Valencia Nutrit financials
| Item | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | ₹1 Cr | ₹1 Cr | ₹8 Cr |
| Operating profit | −₹1 Cr | −₹1 Cr | ₹1 Cr |
| Net profit | −₹1 Cr | −₹1 Cr | ₹1 Cr |
| EPS (₹) | −₹2.26 | −₹2.48 | ₹0.77 |
| Cash from operations | −₹2 Cr | −₹1 Cr | −₹16 Cr |
| Total debt | ₹2 Cr | ₹5 Cr | ₹1 Cr |
| Shareholders' equity | −₹1 Cr | −₹2 Cr | ₹37 Cr |
Valencia Nutrit shareholding pattern
| Holder | 30 Sep 2025 | 31 Dec 2025 | 12 Feb 2026 | 31 Mar 2026 | 11 Jun 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 61.94% | 61.94% | 64.18% | 61.91% | 66.92% | 64.18% |
| Non-institutions | 38.06% | 38.06% | 35.82% | 38.09% | 33.08% | 35.82% |
Valencia Nutrit vs peers
The listed Pharma & Healthcare companies nearest to Valencia Nutrit by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| SMRUTHIORGSmruthi Organic | — | — | — | ₹135 Cr | — | — |
| LACTOSELactose India | — | — | — | ₹132 Cr | — | — |
| VALENCIAValencia Nutrit | — | — | — | ₹132 Cr | — | — |
| PARPar Drugs And Chemicals | ₹105.25 | −2.64% | +1.7% | ₹130 Cr | 9.9 | — |
| ASPIRAAspira Pathlab | — | — | — | ₹125 Cr | — | — |
| PARNAXLABParnax Lab | ₹108.95 | −3.52% | — | ₹125 Cr | 10.6 | — |
| KREBSBIOKrebs Biochemicals and Industries | ₹57.16 | −5.99% | −20.6% | ₹123 Cr | — | — |
Ask anything about Valencia Nutrit
Pivot answers on the live chart with evidence you can check, and tests strategies against VALENCIA's own history. Try: “Why has VALENCIA moved over the last three months?” · “Backtest a 50-day moving-average crossover on VALENCIA over five years” · “Compare VALENCIA with SMRUTHIORG on margins and valuation”
Frequently asked questions about Valencia Nutrit
What is the market cap of Valencia Nutrit?
Valencia Nutrit's market capitalisation is ₹132 Cr (₹132 Cr) at the 19 Oct 2026 close, ranking 2508th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Valencia Nutrit?
Return on equity was 2.9% in FY25 and return on capital employed was 3.2% in FY25 (standalone figures).
Is Valencia Nutrit a debt-free company?
Valencia Nutrit is close to debt-free: its debt-to-equity ratio was 0.04 in FY25.
What is the shareholding pattern of Valencia Nutrit?
As of 30 Jun 2026: promoters 64.18%, non-institutions 35.82%.
Who are Valencia Nutrit's competitors?
The listed Pharma & Healthcare companies closest to Valencia Nutrit by market cap are Smruthi Organic, Lactose India, Par Drugs And Chemicals, Aspira Pathlab, Parnax Lab and Krebs Biochemicals and Industries.
Is Valencia Nutrit a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Valencia Nutrit's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on VALENCIA against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with V · all NSE stocks · this page as text